Staccato Loxapine Multidose PK

Alexza Pharmaceuticals, Inc.40 enrolled

Overview

The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.

The purpose of the present Phase 1 study in schizophrenic patients is to assess the safety and pharmacokinetics of multiple doses of Staccato Loxapine given within a 24 hour time period. The study will be conducted in schizophrenic patients who are on chronic, stable antipsychotic medication. Patients meeting entry criteria will be randomized to one of three dose sequences of Staccato Loxapine or to Staccato Placebo. Following administration of medications, safety, tolerability and pharmacokinetic assessments will be conducted at serial time points.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Volunteers on Chronic, Stable Antipsychotic Regimens

Interventions

A - 10 mg loxapine q 4 h x 3 (30 mg total)DRUG

loxapine aerosol inhalation high dose regimen (30 mg total)

B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)DRUG

loxapine aerosol inhalation middle dose regimen (20 mg total)

C - 5 mg loxapine q 4 h x 3 (15 mg total)DRUG

loxapine aerosol inhalation low dose regimen (15 mg total)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria include: 1. Male and female subjects between the ages of 18 to 65 years, inclusive. 2. Subjects who are on stable, oral, chronic (\>2 mos) antipsychotic medication regimen and who are able to tolerate the rapid oral dose taper and substitution regimen. Exclusion Criteria include: 1. Subjects who are currently treated with injectable depot neuroleptics within one dose interval must be excluded. 2. Subjects who have received loxapine or amoxapine within the last 30 days must be excluded. 3. Subjects with a history of allergy or intolerance to dibenzoxazepines (loxapine and amoxapine) must be excluded. 4. Subjects with a history of movement disorders including Parkinson's disease or a history of neuroleptic malignant syndrome must be excluded. 5. Subjects who have a history within the past year of drug or alcohol dependence or abuse as defined by DSM-4 must be excluded.

Locations (1)

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Outcomes

Primary Outcomes

PK parameters: tmax, Cmax, AUClast, AUCinf, ke, t1/2 and clearance will be estimated for each subject and for the population using noncompartmental methods.

Time frame: 48 hours

Secondary Outcomes

Plasma concentration-time (PK) profiles will be produced for each subject and a mean PK profile for subjects completing for each dose group

Time frame: 24 hours

Tolerability will be assessed based on treatment emergent adverse events, vital signs, ECG and a visual-analog sedation scale.

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.